A recently-developed testing method called Genomic Allergen Rapid Detection (GARD) could prove a valuable tool for the e-cig industry, claims a new study sponsored by Imperial Brands’ Fontem Ventures.
Sign up to access our business and regulatory briefings and get the most updated news, insights and our expert analysis to keep you on top of worldwide industry trends.
By signing up you agree to our Terms and Conditions Please note trial access may take up to 24 hours to be granted as access must be qualified by a member of the ECigIntelligence team.
